Public consultation on interim decisions to amend the Poisons Standard - ACMS, ACCS, Joint ACMS-ACCS, November 2021

Closed 11 Apr 2022

Opened 10 Mar 2022

Feedback updated 1 Dec 2022

We asked

Between 10 March 2022 to 11 April 2022, we sought submissions from the public on the proposed interim decisions which followed the November 2021 meetings of the Advisory Committees on Medicines and Chemicals Scheduling. Respondents were given the choice to indicate their support or opposition to the proposed amendments using survey buttons, with or without a written response.

You said

We received a total of 41 responses for the interim decision consultation, 31 with written components. The majority of responses were in relation to the proposal for cannabis and THC.

The number of votes in opposition for the proposal for cannabis and THC was 25 and 5 fully supportive of the proposed interim decision.

A total of 13 responses were received for meloxicam, 8 in opposition and 5 in full support.

For astrodimer, a total of 13 responses were received, 5 in opposition, 1 in partial support and 4 in full support of the proposed interim decision.

There was a total of 13 responses for choline salicylate, 5 opposing the interim decision, 2 in partial support and 3 in full support.

A total of 9 responses were received for flurbiprofen, 4 in opposition, 1 in partial support and 4 in full support of the interim decision.

For cis-jasmone a total of 8 responses were received, 3 in opposition, 1 in partial support and 4 in full support.

There was a total of 7 responses received for the interim decision in relation to chromates and chromium trioxide. Of these 3 were in opposition, 2 in partial support and 2 in full support.

We did

The Delegate considered all submissions prior to making their final decisions on these substances. The final decisions for substances other than cannabis and THC were published on the 23 May 2022. Following further advice from independent experts, the final decision for cannabis and THC was published on 15 November 2022. 

Overview

Scheduling amendments referred to expert advisory committee

This consultation is for interim decisions made in relation to applications to amend the Poisons Standard, following advice sought at the 3-4 November 2021 meetings of the Advisory Committee on Medicines Scheduling (ACMS) and the Advisory Committee on Chemicals Scheduling (ACCS).

The closing date for this consultation is close of business 11 April 2022. All submissions received by the deadline will be considered by the delegate before they make a final decision.

The interim decisions under this consultation are detailed in the public notice of interim decisions of November 2021 published on 10 March 2022.

Substances for which public comment is sought:

  • Item 2.1 - Astodrimer sodium
  • Item 2.2 - Flurbiprofen
  • Item 3.1 - Cis-jasmone
  • Item 3.2 - Cannabis and tetrahydrocannabinols
  • Item 3.3 - Meloxicam
  • Item 3.4 - Choline salicylate
  • Item 4.1 - Chromates and chromium trioxide

What happens next

All public submissions will be published on the TGA website at Public submissions on scheduling matters, unless marked confidential or indicated otherwise in the submission information (see Privacy and your Personal information).

Public submissions are an important part of the process for amending the Poison Standard, and are published on the TGA website using the consultation hub.  Submissions by the public may not reflect the views of the Department of Health or TGA.  Published submissions should not be taken as being endorsed by the Department or TGA.

Following consideration of public submissions received before the closing date and advice from the expert advisory committees, decisions on the proposed amendments are anticipated to be published as final decisions on the TGA website: Scheduling delegate's final decisions  in April 2022.

 

Audiences

  • General public

Interests

  • Legislation